Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock News
Jan 7, 2025 - globenewswire.com
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 19, 2024 - globenewswire.com
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Nov 13, 2024 - globenewswire.com
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Oct 30, 2024 - globenewswire.com
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
Lexeo Therapeutics, Inc. Common Stock Quantitative Score
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Lexeo Therapeutics, Inc. Common Stock Earnings & Revenue
Lexeo Therapeutics, Inc. Common Stock Financials
Table Compare
Compare LXEO metrics with: | |||
|---|---|---|---|
Earnings & Growth | LXEO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LXEO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LXEO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LXEO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Lexeo Therapeutics, Inc. Common Stock Income
Lexeo Therapeutics, Inc. Common Stock Balance Sheet
Lexeo Therapeutics, Inc. Common Stock Cash Flow
Lexeo Therapeutics, Inc. Common Stock Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Lexeo Therapeutics, Inc. Common Stock Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Lexeo Therapeutics, Inc. Common Stock Executives
| Name | Role |
|---|---|
| Mr. R. Nolan Townsend | Chief Executive Officer & Director |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research |
| Ms. Jenny R. Robertson J.D. | Chief Business & Legal Officer |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
| Mr. Rand Monaghan | Vice President of Finance |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. R. Nolan Townsend | Chief Executive Officer & Director | Male | 1981 | 864.34K |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research | 1974 | 623.4K | |
| Ms. Jenny R. Robertson J.D. | Chief Business & Legal Officer | Female | 1975 | 617.9K |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer | -- | ||
| Mr. Rand Monaghan | Vice President of Finance | Male | -- |
Lexeo Therapeutics, Inc. Common Stock Insider Trades
| Date | 17 Jan |
| Name | Rasbach Kyle |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40875 |
| Date | 17 Jan |
| Name | Rasbach Kyle |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 245250 |
| Date | 7 Jan |
| Name | Townsend Richard Nolan |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 103750 |
| Date | 7 Jan |
| Name | Townsend Richard Nolan |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 207500 |
| Date | 7 Jan |
| Name | Otero Jose Manuel |
| Role | Chief Technical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26250 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 17 Jan | Rasbach Kyle | Chief Financial Officer | Acquired | A-Award | 40875 |
| 17 Jan | Rasbach Kyle | Chief Financial Officer | Acquired | A-Award | 245250 |
| 7 Jan | Townsend Richard Nolan | Chief Executive Officer | Acquired | A-Award | 103750 |
| 7 Jan | Townsend Richard Nolan | Chief Executive Officer | Acquired | A-Award | 207500 |
| 7 Jan | Otero Jose Manuel | Chief Technical Officer | Acquired | A-Award | 26250 |